Hernandez Beatriz S, Saffati Gal, Lowrey Katherine A, Reddy Amit, Park Bridget S, Song Jeffrey J, Lyon Gabrielle, Khera Mohit
Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA.
Center for Muscle-centric Medicine, The Woodlands, TX, USA.
Transl Androl Urol. 2025 Jul 30;14(7):1842-1848. doi: 10.21037/tau-2025-51. Epub 2025 Jul 28.
Testosterone therapy for low libido in women has become increasingly prevalent in recent years. While numerous testosterone formulations exist and have been studied in women, there has been little data assessing the safety and efficacy of subcutaneous testosterone pellet use in this population. The primary objective of this study is to understand the biochemical effects and side effect profile of female patients who underwent testosterone pellet insertion in a clinical practice.
A retrospective chart review of female patients who underwent testosterone pellet insertion from 2009 to 2022 was undertaken. Women taking 75 and 100 mg testosterone pellets were identified and analyzed for biochemical and clinical data. Analysis of variance was performed to determine statistical significance of laboratory values over duration of testosterone pellet insertion.
A total of 220 pellet insertions were performed across the two cohorts. The administration of 75 mg testosterone pellets did not result in a significant change in trough testosterone levels (P=0.51) compared to baseline throughout the treatment period, nor did it significantly affect hematocrit levels (P=0.96) or systolic blood pressure (SBP) (P=0.87). Two patients (10.5%) reported genitourinary side effects during the study period. In the cohort receiving 100 mg testosterone pellets, a significant increase in testosterone levels was observed over the study period (P=0.01), with no significant changes in hematocrit (P=0.78) or SBP (P=0.70). Two patients in this group were initiated on new antihypertensive medications during the course of treatment. No adverse effects were reported.
Testosterone pellets of 100 mg result in a statistically significant increase in testosterone levels. Neither the 75 nor 100 mg doses led to a significant increase in erythrocytosis or SBP. Additionally, both dosages are associated with minimal side effects. These findings suggest that regulated testosterone pellet administration offers a safe biochemical profile for women with low libido.
近年来，睾酮疗法用于治疗女性性欲减退的情况日益普遍。虽然存在多种睾酮制剂并已在女性中进行了研究，但评估皮下植入睾酮丸剂在该人群中的安全性和有效性的数据很少。本研究的主要目的是了解在临床实践中接受睾酮丸剂植入的女性患者的生化效应和副作用情况。
对2009年至2022年期间接受睾酮丸剂植入的女性患者进行回顾性病历审查。确定服用75毫克和100毫克睾酮丸剂的女性，并分析其生化和临床数据。进行方差分析以确定睾酮丸剂植入期间实验室值的统计学显著性。
两个队列共进行了220次丸剂植入。在整个治疗期间，与基线相比，服用75毫克睾酮丸剂后谷值睾酮水平无显著变化（P = 0.51），对血细胞比容水平（P = 0.96）或收缩压（SBP）（P = 0.87）也无显著影响。两名患者（10.5%）在研究期间报告了泌尿生殖系统副作用。在接受100毫克睾酮丸剂的队列中，研究期间观察到睾酮水平显著升高（P = 0.01），血细胞比容（P = 0.78）或SBP（P = 0.70）无显著变化。该组中有两名患者在治疗过程中开始使用新的抗高血压药物。未报告不良反应。
100毫克的睾酮丸剂可使睾酮水平在统计学上显著升高。75毫克和100毫克剂量均未导致红细胞增多症或SBP显著升高。此外，两种剂量的副作用都很小。这些发现表明，规范的睾酮丸剂给药为性欲减退的女性提供了安全的生化特征。
